Skip to main content
Erschienen in: Pediatric Drugs 6/2008

01.11.2008 | Commentary

Drug Delivery Systems in Children

verfasst von: Dr Stephen Lowis

Erschienen in: Pediatric Drugs | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Excerpt

The efficacy of a given drug is dependent upon the reliability of delivery to its site of action; the drug must reach its target to have an effect. At the simplest level, the preparation of a drug, its route of administration, and its disposition according to pharmacokinetic properties define its delivery; these factors are particularly important in pediatric practice. For the last 20 years, modification of drug disposition has been possible, and a number of specific delivery systems have appeared with this in mind. Examples include polymeric carriers, reservoirs and matrix devices, liposomal preparations, and modification of molecules to influence their antigenicity. Selective targeting of carrier molecules, to deliver a chosen drug to its site of action, has been attempted. All of these strategies aim to improve activity or reduce toxicity. …
Fußnoten
1
The use of trade names is for product identification purposes only and does not imply endorsement
 
Literatur
1.
Zurück zum Zitat Nowak-Gottl U, Heinecke A, von Kries R, et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001 Aug 1; 103(3): 165–72PubMedCrossRef Nowak-Gottl U, Heinecke A, von Kries R, et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001 Aug 1; 103(3): 165–72PubMedCrossRef
2.
Zurück zum Zitat Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896–904PubMedCrossRef Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896–904PubMedCrossRef
3.
Zurück zum Zitat Rodriguez T, Baumgarten E, Fengler R, et al. Long-term infusion of L-as-paraginase: an alternative to intramuscular injection? [in German]. Klin Padiatr 1995; 109(4): 207–10CrossRef Rodriguez T, Baumgarten E, Fengler R, et al. Long-term infusion of L-as-paraginase: an alternative to intramuscular injection? [in German]. Klin Padiatr 1995; 109(4): 207–10CrossRef
4.
Zurück zum Zitat Tuttle CB. Intramuscular injections and bioavailability. Am J Hosp Pharm 1977 Sep; 34(9): 965–8PubMed Tuttle CB. Intramuscular injections and bioavailability. Am J Hosp Pharm 1977 Sep; 34(9): 965–8PubMed
5.
Zurück zum Zitat Ellison JA, Patel L, Ray DW, et al. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000 Apr; 105 (4 Pt 1): 794–9PubMedCrossRef Ellison JA, Patel L, Ray DW, et al. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000 Apr; 105 (4 Pt 1): 794–9PubMedCrossRef
6.
Zurück zum Zitat Ozon A, Cetinkaya S, Alikasifoglu A, et al. Inappropriate use of potent topical glucocorticoids in infants. J Pediatr Endocrinol Metab 2007 Feb; 20(2): 219–25PubMedCrossRef Ozon A, Cetinkaya S, Alikasifoglu A, et al. Inappropriate use of potent topical glucocorticoids in infants. J Pediatr Endocrinol Metab 2007 Feb; 20(2): 219–25PubMedCrossRef
7.
Zurück zum Zitat Guven A, Gulumser O, Ozgen T. Cushing’s syndrome and adrenocortical insufficiency caused by topical steroids: misuse or abuse? J Pediatr Endocrinol Metab 2007 Nov; 20(11): 1173–82PubMedCrossRef Guven A, Gulumser O, Ozgen T. Cushing’s syndrome and adrenocortical insufficiency caused by topical steroids: misuse or abuse? J Pediatr Endocrinol Metab 2007 Nov; 20(11): 1173–82PubMedCrossRef
8.
Zurück zum Zitat Osorio JE, Zuleger CL, Burger M, et al. Immune responses to hepatitis B surface antigen following epidermal powder immunization. Immunol Cell Biol 2003 Feb; 81(1): 52–8PubMedCrossRef Osorio JE, Zuleger CL, Burger M, et al. Immune responses to hepatitis B surface antigen following epidermal powder immunization. Immunol Cell Biol 2003 Feb; 81(1): 52–8PubMedCrossRef
9.
Zurück zum Zitat Wolf AR, Stoddart PA, Murphy PJ, et al. Rapid skin anaesthesia using high velocity lignocaine particles: a prospective placebo controlled trial. Arch Dis Child 2002 Apr; 86(4): 309–12PubMedCrossRef Wolf AR, Stoddart PA, Murphy PJ, et al. Rapid skin anaesthesia using high velocity lignocaine particles: a prospective placebo controlled trial. Arch Dis Child 2002 Apr; 86(4): 309–12PubMedCrossRef
10.
Zurück zum Zitat Burkman RT. Transdermal hormonal contraception: benefits and risks. Am J Obstet Gynecol 2007; 134: e1–6 Burkman RT. Transdermal hormonal contraception: benefits and risks. Am J Obstet Gynecol 2007; 134: e1–6
11.
Zurück zum Zitat Hunt A, Goldman A, Devine T, et al. Transdermal fentanyl for pain relief in a paediatric palliative care population. Palliat Med 2001; 15: 405–12PubMedCrossRef Hunt A, Goldman A, Devine T, et al. Transdermal fentanyl for pain relief in a paediatric palliative care population. Palliat Med 2001; 15: 405–12PubMedCrossRef
12.
Zurück zum Zitat Horimoto Y, Tomie H, Hanzawa K, et al. Scopolamine patch reduces postoperative emesis in paediatric patients following strabismus surgery. Can J Anaesth 1991; 38: 441–4PubMedCrossRef Horimoto Y, Tomie H, Hanzawa K, et al. Scopolamine patch reduces postoperative emesis in paediatric patients following strabismus surgery. Can J Anaesth 1991; 38: 441–4PubMedCrossRef
13.
Zurück zum Zitat Zernikow B, Michel E, Anderson B. Transdermal fentanyl in childhood and adolescence: a comprehensive literature review. J Pain 2007; 8: 187–207PubMedCrossRef Zernikow B, Michel E, Anderson B. Transdermal fentanyl in childhood and adolescence: a comprehensive literature review. J Pain 2007; 8: 187–207PubMedCrossRef
14.
Zurück zum Zitat Collins JJ, Dunkel IJ, Gupta SK, et al. Transdermal fentanyl in children with cancer pain: feasibility, tolerability, and pharmacokinetic correlates. J Pediatr 1999; 134: 319–23PubMedCrossRef Collins JJ, Dunkel IJ, Gupta SK, et al. Transdermal fentanyl in children with cancer pain: feasibility, tolerability, and pharmacokinetic correlates. J Pediatr 1999; 134: 319–23PubMedCrossRef
15.
Zurück zum Zitat Power I. Fentanyl HCl iontophoretic transdermal system (ITS): clinical application of iontophoretic technology in the management of acute postoperative pain. Br J Anaesth 2007 Jan; 98(1): 4–11PubMedCrossRef Power I. Fentanyl HCl iontophoretic transdermal system (ITS): clinical application of iontophoretic technology in the management of acute postoperative pain. Br J Anaesth 2007 Jan; 98(1): 4–11PubMedCrossRef
16.
Zurück zum Zitat Halhal M, Renard G, Courtois Y, et al. Iontophoresis: from the lab to the bed side. Exp Eye Res 2004 Mar; 78(3): 751–7PubMedCrossRef Halhal M, Renard G, Courtois Y, et al. Iontophoresis: from the lab to the bed side. Exp Eye Res 2004 Mar; 78(3): 751–7PubMedCrossRef
17.
Zurück zum Zitat Fujimoto T. Pharmacokinetics of intrathecal chemotherapy and clinical problems [in Japanese]. Gan To Kagaku Ryoho 1984 Aug; 11(8): 1536–42PubMed Fujimoto T. Pharmacokinetics of intrathecal chemotherapy and clinical problems [in Japanese]. Gan To Kagaku Ryoho 1984 Aug; 11(8): 1536–42PubMed
18.
Zurück zum Zitat Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975 Jul 24; 293(4): 161–6PubMedCrossRef Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975 Jul 24; 293(4): 161–6PubMedCrossRef
19.
Zurück zum Zitat Bleyer WA, Poplack DG. Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 1979; 6(3): 207–13PubMedCrossRef Bleyer WA, Poplack DG. Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 1979; 6(3): 207–13PubMedCrossRef
20.
Zurück zum Zitat Phuphanich S, Maria B, Braeckman R, et al. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 2007 Jan; 81(2): 201–8PubMedCrossRef Phuphanich S, Maria B, Braeckman R, et al. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 2007 Jan; 81(2): 201–8PubMedCrossRef
21.
Zurück zum Zitat Biggart E, Bush A. Antiasthmatic drug delivery in children. Paediatr Drugs 2002; 4(2): 85–93PubMed Biggart E, Bush A. Antiasthmatic drug delivery in children. Paediatr Drugs 2002; 4(2): 85–93PubMed
22.
Zurück zum Zitat Sermet-Gaudelus I, Le Cocguic Y, Ferroni A, et al. Nebulized antibiotics in cystic fibrosis. Paediatr Drugs 2002; 4(7): 455–67PubMed Sermet-Gaudelus I, Le Cocguic Y, Ferroni A, et al. Nebulized antibiotics in cystic fibrosis. Paediatr Drugs 2002; 4(7): 455–67PubMed
23.
Zurück zum Zitat Cheer SM, Warner GT, Easthope SE. Formoterol delivered by Turbuhaler: in pediatric asthma. Paediatr Drugs 2003; 5(1): 63–8 discussion 9PubMed Cheer SM, Warner GT, Easthope SE. Formoterol delivered by Turbuhaler: in pediatric asthma. Paediatr Drugs 2003; 5(1): 63–8 discussion 9PubMed
24.
Zurück zum Zitat De Benedictis FM, Selvaggio D. Use of inhaler devices in pediatric asthma. Paediatr Drugs 2003; 5(9): 629–38PubMedCrossRef De Benedictis FM, Selvaggio D. Use of inhaler devices in pediatric asthma. Paediatr Drugs 2003; 5(9): 629–38PubMedCrossRef
25.
Zurück zum Zitat Gulliver T, Morton R, Eid N. Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. Paediatr Drugs 2007; 9(3): 185–94PubMedCrossRef Gulliver T, Morton R, Eid N. Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. Paediatr Drugs 2007; 9(3): 185–94PubMedCrossRef
26.
Zurück zum Zitat Mitchell JP, Coppolo DP, Nagel MW. Electrostatics and inhaled medications: influence on delivery via pressurized metered-dose inhalers and add-on devices. Respir Care 2007 Mar; 52(3): 283–300PubMed Mitchell JP, Coppolo DP, Nagel MW. Electrostatics and inhaled medications: influence on delivery via pressurized metered-dose inhalers and add-on devices. Respir Care 2007 Mar; 52(3): 283–300PubMed
27.
Zurück zum Zitat Wildhaber JH, Waterer GW, Hall GL, et al. Reducing electrostatic charge on spacer devices and bronchodilator response. Br J Clin Pharmacol 2000 Sep; 50(3): 277–80PubMedCrossRef Wildhaber JH, Waterer GW, Hall GL, et al. Reducing electrostatic charge on spacer devices and bronchodilator response. Br J Clin Pharmacol 2000 Sep; 50(3): 277–80PubMedCrossRef
28.
Zurück zum Zitat Vaghi A, Berg E, Liljedahl S, et al. In vitro comparison of nebulised budesonide (Pulmicort respules) and beclomethasone dipropionate (Clenil per aerosol). Pulm Pharmacol Ther 2005; 18(2): 151–3PubMedCrossRef Vaghi A, Berg E, Liljedahl S, et al. In vitro comparison of nebulised budesonide (Pulmicort respules) and beclomethasone dipropionate (Clenil per aerosol). Pulm Pharmacol Ther 2005; 18(2): 151–3PubMedCrossRef
29.
Zurück zum Zitat Barry PW, O’Callaghan C. The output of budesonide from spacer devices assessed under simulated breathing conditions. J Allergy Clin Immunol 1999 Dec; 104(6): 1205–10PubMedCrossRef Barry PW, O’Callaghan C. The output of budesonide from spacer devices assessed under simulated breathing conditions. J Allergy Clin Immunol 1999 Dec; 104(6): 1205–10PubMedCrossRef
30.
Zurück zum Zitat O’Callaghan C, White J, Jackson J, et al. Delivery of nebulized budesonide is affected by nebulizer type and breathing pattern. J Pharm Pharmacol 2005 Jun; 57(6): 787–90PubMedCrossRef O’Callaghan C, White J, Jackson J, et al. Delivery of nebulized budesonide is affected by nebulizer type and breathing pattern. J Pharm Pharmacol 2005 Jun; 57(6): 787–90PubMedCrossRef
31.
Zurück zum Zitat Zindani GN, Streetman DD, Streetman DS, et al. Adherence to treatment in children and adolescent patients with cystic fibrosis. J Adolesc Health 2006; 38: 13–7PubMedCrossRef Zindani GN, Streetman DD, Streetman DS, et al. Adherence to treatment in children and adolescent patients with cystic fibrosis. J Adolesc Health 2006; 38: 13–7PubMedCrossRef
32.
Zurück zum Zitat Garvie PA, Lensing S, Rai SN. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS. Pediatrics 2007; 119: e893–9PubMedCrossRef Garvie PA, Lensing S, Rai SN. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS. Pediatrics 2007; 119: e893–9PubMedCrossRef
33.
Zurück zum Zitat Sparreboom A, van Tellingen O, Nooijen WJ, et al. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996 May 1; 56(9): 2112–5PubMed Sparreboom A, van Tellingen O, Nooijen WJ, et al. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996 May 1; 56(9): 2112–5PubMed
34.
Zurück zum Zitat Buggins TR, Dickinson PA, Taylor G. The effects of pharmaceutical excipients on drug disposition. Adv Drug Deliv Rev 2007 Dec 22; 59(15): 1482–503PubMedCrossRef Buggins TR, Dickinson PA, Taylor G. The effects of pharmaceutical excipients on drug disposition. Adv Drug Deliv Rev 2007 Dec 22; 59(15): 1482–503PubMedCrossRef
35.
Zurück zum Zitat Fanta S, Jonsson S, Backman JT, et al. Developmental pharmacokinetics of ciclosporin: a population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol 2007 Dec; 64(6): 772–84PubMed Fanta S, Jonsson S, Backman JT, et al. Developmental pharmacokinetics of ciclosporin: a population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol 2007 Dec; 64(6): 772–84PubMed
36.
Zurück zum Zitat Pollard SG. Pharmacologic monitoring and outcomes of cyclosporine. Transplant Proc 2004 Mar; 36(2 Suppl.): 404S–7SPubMedCrossRef Pollard SG. Pharmacologic monitoring and outcomes of cyclosporine. Transplant Proc 2004 Mar; 36(2 Suppl.): 404S–7SPubMedCrossRef
37.
Zurück zum Zitat Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc 2004 Mar; 36(2 Suppl.): 378S–91SPubMedCrossRef Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc 2004 Mar; 36(2 Suppl.): 378S–91SPubMedCrossRef
38.
Zurück zum Zitat Dubus JC, Anhoj J. A review of once-daily delivery of anti-asthmatic drugs in children. Pediatr Allergy Immunol 2003; 14: 4–9PubMedCrossRef Dubus JC, Anhoj J. A review of once-daily delivery of anti-asthmatic drugs in children. Pediatr Allergy Immunol 2003; 14: 4–9PubMedCrossRef
39.
Zurück zum Zitat Lonnerholm G, Foucard T, Lindstrom B. Treatment of chronic asthma in children with a sustained-release preparation of theophylline in addition to beta 2-stimulating agents. Eur J Respir DisSuppl 1980; 109: 95–7 Lonnerholm G, Foucard T, Lindstrom B. Treatment of chronic asthma in children with a sustained-release preparation of theophylline in addition to beta 2-stimulating agents. Eur J Respir DisSuppl 1980; 109: 95–7
40.
Zurück zum Zitat Genton P. Progress in pharmaceutical development presentation with improved pharmacokinetics: a new formulation for valproate. Acta Neurol Scand Suppl 2005; 182: 26–32PubMedCrossRef Genton P. Progress in pharmaceutical development presentation with improved pharmacokinetics: a new formulation for valproate. Acta Neurol Scand Suppl 2005; 182: 26–32PubMedCrossRef
41.
Zurück zum Zitat Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Pshychiatry 2001; 40: 307–14CrossRef Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Pshychiatry 2001; 40: 307–14CrossRef
42.
Zurück zum Zitat Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002; 49Suppl. 1: 21–30PubMedCrossRef Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002; 49Suppl. 1: 21–30PubMedCrossRef
43.
Zurück zum Zitat Forssen EA, Ross ME. DaunoXome treatment of solid tumours: preclinical and clinical investigations. J Liposome Research 1994; 4: 481CrossRef Forssen EA, Ross ME. DaunoXome treatment of solid tumours: preclinical and clinical investigations. J Liposome Research 1994; 4: 481CrossRef
44.
Zurück zum Zitat Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 1992 Jun 15; 52(12): 3255–61PubMed Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 1992 Jun 15; 52(12): 3255–61PubMed
45.
Zurück zum Zitat Brown LR, Edelman ER, Fischel-Ghodsian F, et al. Characterization of glucose-mediated insulin release from implantable polymers. J Pharm Sci 1996 Dec; 85(12): 1341–5PubMedCrossRef Brown LR, Edelman ER, Fischel-Ghodsian F, et al. Characterization of glucose-mediated insulin release from implantable polymers. J Pharm Sci 1996 Dec; 85(12): 1341–5PubMedCrossRef
46.
Zurück zum Zitat Gupta P, Vermani K, Garg S. Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov Today 2002 May 15; 7(10): 569–79PubMedCrossRef Gupta P, Vermani K, Garg S. Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov Today 2002 May 15; 7(10): 569–79PubMedCrossRef
47.
Zurück zum Zitat Bourges JL, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 2006 Nov 15; 58(11): 1182–202PubMedCrossRef Bourges JL, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 2006 Nov 15; 58(11): 1182–202PubMedCrossRef
48.
Zurück zum Zitat Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006 Jun; 113(6): 1020–7PubMedCrossRef Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006 Jun; 113(6): 1020–7PubMedCrossRef
49.
Zurück zum Zitat Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev 2008; 60: 1037–55PubMedCrossRef Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev 2008; 60: 1037–55PubMedCrossRef
50.
Zurück zum Zitat Drin G, Rousselle C, Scherrmann JM, et al. Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors. AAPS PharmSci 2002; 4: E26PubMedCrossRef Drin G, Rousselle C, Scherrmann JM, et al. Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors. AAPS PharmSci 2002; 4: E26PubMedCrossRef
51.
Zurück zum Zitat Day FH, Zhang Y, Clair P, et al. Induction of antigen-specific CTL responses using antigens conjugated to short peptide vectors. J Immunol 2003 Feb 1; 170(3): 1498–503PubMed Day FH, Zhang Y, Clair P, et al. Induction of antigen-specific CTL responses using antigens conjugated to short peptide vectors. J Immunol 2003 Feb 1; 170(3): 1498–503PubMed
52.
Zurück zum Zitat Rousselle C, Clair P, Lefauconnier JM, et al. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 2000 Apr; 57(4): 679–86PubMed Rousselle C, Clair P, Lefauconnier JM, et al. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 2000 Apr; 57(4): 679–86PubMed
Metadaten
Titel
Drug Delivery Systems in Children
verfasst von
Dr Stephen Lowis
Publikationsdatum
01.11.2008
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 6/2008
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.2165/0148581-200810060-00002

Weitere Artikel der Ausgabe 6/2008

Pediatric Drugs 6/2008 Zur Ausgabe

Acknowledgments

Acknowledgment

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.